Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

4D Molecular Therapeutics (FDMT) EBITDA Margin (2020 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed EBITDA Margin for 6 consecutive years, with 17.29% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin rose 561171729.0% to 17.29% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 187.24% through Dec 2025, up 50749114.0% year-over-year, with the annual reading at 187.24% for FY2025, 50749114.0% up from the prior year.
  • EBITDA Margin for Q4 2025 was 17.29% at 4D Molecular Therapeutics, up from 67983.33% in the prior quarter.
  • The five-year high for EBITDA Margin was 192905.26% in Q4 2023, with the low at 5611700.0% in Q4 2024.
  • Average EBITDA Margin over 5 years is 451811.86%, with a median of 11774.35% recorded in 2023.
  • The sharpest move saw EBITDA Margin tumbled -580460526bps in 2024, then skyrocketed 561171729bps in 2025.
  • Over 5 years, EBITDA Margin stood at 26917.39% in 2021, then surged by 91bps to 2303.13% in 2022, then soared by 8476bps to 192905.26% in 2023, then crashed by -3009bps to 5611700.0% in 2024, then skyrocketed by 100bps to 17.29% in 2025.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 17.29%, 67983.33%, and 396373.33% for Q4 2025, Q3 2025, and Q2 2025 respectively.